Advanced Filters
noise

Mbeya, Tanzania Clinical Trials

A listing of Mbeya, Tanzania clinical trials actively recruiting patients volunteers.

Found 9 clinical trials

SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian Youth

The overall objectives of this proposal are to support positive coping strategies that bolster mental health and lead to improved HIV outcomes among Young People Living with HIV (YPLWH). The central hypothesis is that SYV (Sauti ya Vijana, The Voice of Youth) will be effective to improve antiretroviral therapy (ART) …

10 - 24 years of age Both Phase N/A

Dynamic CDSA to Manage Sick Children in Tanzania

This study aims to reduce morbidity and mortality among children and mitigate antimicrobial resistance using a novel clinical decision support algorithm, enhanced with point-of-care technologies to help health workers in primary health care settings in Tanzania. Furthermore, the tool provides opportunities to improve supervision and mentorship of health workers and …

1 - 14 years of age Both Phase N/A
F Fairoez Ryklief, Dr

BTZ-043 Dose Evaluation in Combination and Selection

This is a phase 2B, open label study, that will compare the safety and efficacy of three experimental regimens consisting of bedaquiline and delamanid in combination with different doses of BTZ-043, a novel antibiotic, in adult participants with newly diagnosed, drug-sensitive pulmonary tuberculosis. Participants will be assigned to receive either …

18 - 64 years of age Both Phase 2
P Pauline Howell, MD

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

The goal of this clinical trial is to evaluate 3 dose levels of TBAJ876 for 8 weeks in combination with pretomanid and linezolid, compared to 8 weeks of Isoniazid, rifampicin, pyrazinamide and ethambutol (2HRZE), in adult participants with newly diagnosed, smear-positive, pulmonary drug sensitive tuberculosis (DS-TB). The main questions the …

18 - 65 years of age Both Phase 2
I Irene Andia- Biraro, MD, MMed, PhD

Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus

Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB and HIV and it has been estimated that 15-30% of TB disease may be attributable to diabetes globally. This may be expected …

18 - 100 years of age Both Phase 3
C Celso Khosa, Dr

TB-CAPT EXULTANT - HIV

The overall aim of this study is to assess the potential of an expanded TB testing strategy to increase the number of HIV-positive patients with microbiologically diagnosed TB who are started on treatment in adult wards of sub-Saharan Africa.

18 - 100 years of age Both Phase N/A
L Lee-Ann Davids, Dr

PanACEA - STEP2C -01

This is a phase 2B/C, open label platform study that will compare the efficacy, safety of 3 experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis. In stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing …

18 - 65 years of age Both Phase 2
B Belinda Van Rooyen

A Pan-TB Regimen Targeting Host and Microbe

This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It will also test whether the addition …

18 - 65 years of age Both Phase 2/3
L Lucas Maganga, MD, MPH

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-acting bNAbs, alone and in …

18 - 50 years of age Both Phase 1

Rewrite in simple language using AI